Emerging Cytomegalovirus Management Strategies After Solid Organ Transplantation: Challenges and Opportunities

Transplant and Oncology (M Ison, Section Editor)

DOI: 10.1007/s11908-014-0419-8

Cite this article as:
Beam, E., Dioverti, V. & Razonable, R.R. Curr Infect Dis Rep (2014) 16: 419. doi:10.1007/s11908-014-0419-8
Part of the following topical collections:
  1. Topical Collection on Transplant and Oncology


Cytomegalovirus (CMV) remains as one of the most common pathogens after solid organ transplantation (SOT). During the past year, management guidelines were updated, and numerous studies were published—all collectively emphasizing the ongoing efforts to improve management of CMV after SOT. Improvement in laboratory diagnostics was aided by the WHO international calibration standard for nucleic acid testing, which allows for meaningful comparison of viral load values among laboratories. The potential translation of methods for assessing CMV-specific cellular immunity could provide tools for CMV risk assessment and management. Efforts continue to optimize antiviral strategies for CMV disease prevention and treatment. CMV vaccines continue to be tested in various stages of clinical trials. Novel anti-CMV drugs are being developed, including agents that have been used as compassionate therapy for treatment of drug-resistant CMV. In this article, the authors review recent developments on CMV and discuss their implications in CMV management after transplantation.


Cytomegalovirus Prophylaxis Transplantation Viral load Valganciclovir Outcomes 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of Medicine, and the William J von Liebig Center for Transplantation and Clinical RegenerationMayo Clinic College of MedicineRochesterUSA

Personalised recommendations